share_log

基石藥業-B：(I)根據首次公開發售後受限制股份獎勵計劃授出受限制股份單位；及(II)根據首次公開發售後僱員持股計劃授出購股權

CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP

香港交易所 ·  Mar 28 10:45
Summary by Moomoo AI
基石藥業於2024年3月28日宣布，根據首次公開發售後受限制股份獎勵計劃及僱員持股計劃，向104名受限制股份單位承授人授出合共11,197,900份受限制股份單位，以及向107名購股權承授人授出合共11,202,900份購股權。其中包括向三名董事授予合共3,890,000份受限制股份單位及購股權，以及向僱員（包括高級管理層成員）及一名服務提供者授出餘下的股份單位及購股權。該授出行為旨在激勵員工及承認其對公司的貢獻，並無附帶績效指標。授出的受限制股份單位及購股權將按照一定的歸屬期逐步歸屬給承授人。此外，由於向楊建新博士授出的股份單位及購股權將導致其在過去12個月內獲得的股份超過公司已發行股份總數的1%，根據上市規則，此部分授出需經股東在年度大會上批准。公司將召開股東年度大會以處理相關事宜，並提醒股東及潛在投資者在交易公司股份時需審慎行事。
基石藥業於2024年3月28日宣布，根據首次公開發售後受限制股份獎勵計劃及僱員持股計劃，向104名受限制股份單位承授人授出合共11,197,900份受限制股份單位，以及向107名購股權承授人授出合共11,202,900份購股權。其中包括向三名董事授予合共3,890,000份受限制股份單位及購股權，以及向僱員（包括高級管理層成員）及一名服務提供者授出餘下的股份單位及購股權。該授出行為旨在激勵員工及承認其對公司的貢獻，並無附帶績效指標。授出的受限制股份單位及購股權將按照一定的歸屬期逐步歸屬給承授人。此外，由於向楊建新博士授出的股份單位及購股權將導致其在過去12個月內獲得的股份超過公司已發行股份總數的1%，根據上市規則，此部分授出需經股東在年度大會上批准。公司將召開股東年度大會以處理相關事宜，並提醒股東及潛在投資者在交易公司股份時需審慎行事。
KEYSTONE PHARMACEUTICALS ANNOUNCED ON 28 MARCH 2024 THAT IT HAS GRANTED A TOTAL OF 11,197,900 RESTRICTED SHARES TO 104 RESTRICTED SHARE SUBSCRIBERS UNDER THE INITIAL PUBLIC OFFERING RESTRICTED SHARE AWARD SCHEME AND EMPLOYEE SHAREHOLDING SCHEME AND HAS GRANTED A TOTAL OF 11,202,900 SHARES TO 107 SHARE PURCHASE OPTIONS. This includes the granting of a total of 3,890,000 restricted stock units and share options to the three directors, and the granting of the remaining units and share options to employees (including senior management) and a service provider. The awarding act is designed to motivate employees and recognize their contributions to the company and does not come with performance indicators. The restricted units and share purchase rights granted will be assigned to the grantor on a phased basis according...Show More
KEYSTONE PHARMACEUTICALS ANNOUNCED ON 28 MARCH 2024 THAT IT HAS GRANTED A TOTAL OF 11,197,900 RESTRICTED SHARES TO 104 RESTRICTED SHARE SUBSCRIBERS UNDER THE INITIAL PUBLIC OFFERING RESTRICTED SHARE AWARD SCHEME AND EMPLOYEE SHAREHOLDING SCHEME AND HAS GRANTED A TOTAL OF 11,202,900 SHARES TO 107 SHARE PURCHASE OPTIONS. This includes the granting of a total of 3,890,000 restricted stock units and share options to the three directors, and the granting of the remaining units and share options to employees (including senior management) and a service provider. The awarding act is designed to motivate employees and recognize their contributions to the company and does not come with performance indicators. The restricted units and share purchase rights granted will be assigned to the grantor on a phased basis according to a specified assignment period. In addition, since the share units and purchase rights granted to Dr. Yang Jian-shin will result in his shares acquired in the past 12 months exceeding 1% of the total number of shares issued in the company, according to the Listing Rules, this portion of the grant is subject to approval by the shareholders at the Annual General Meeting. THE COMPANY WILL HOLD AN ANNUAL GENERAL MEETING TO DEAL WITH THE RELEVANT MATTERS AND TO REMIND SHAREHOLDERS AND POTENTIAL INVESTORS TO EXERCISE CAUTION WHEN TRADING THE COMPANY'S SHARES.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more